

# Module 10- Supplements

## Learning Objectives:

At the end of this module you should be able to:

1. List the key micronutrient considerations for optimal fertility
2. Individually prescribe micronutrient supplements to your clients based on their unique needs
3. Appreciate the different types of folate and know how to determine which is best for your client
4. Respond to questions regarding alternative supplements for fertility in light of the available (or lack of) evidence

Fertility rates are improved with the use of a pre-natal supplement.<sup>1</sup> It is recommended that most women take a multivitamin *before* getting pregnant to help fill in nutritional gaps.

## Micronutrient supplements

### Folic acid

The neural tube is the baby's brain and spinal cord and is one of the first components to develop. Folate is essential for the development of the Neural Tube, so inadequate folate can be one of the main reasons for unsuccessful pregnancies. Folate, being a B group vitamin, is water soluble so requires regular replenishment. Insufficient dietary intake of folates for as short as 2-3 weeks has been reported to result in reduced blood concentrations of the vitamin.

It is recommended that all women planning to conceive take 400-500mcg folic acid for 3 months prior to conception.<sup>2</sup> Folic acid is commonly found in prenatal and preconception multivitamin supplements, but be aware that many of these multivitamins won't meet requirements for clients who have increased folate requirements. Women requiring higher doses of folic acid include those with certain folate-enzyme genotypes, previous pregnancies with neural tube defects, diabetes, malabsorption disorders, or obesity, or those who take antifolate medications or smoke, and those with partners who have a male partner who has a moderate risk of poor folate bioavailability.<sup>3 4</sup> It is recommended that women with moderate risk take at least 1mg folic acid per day and recommended that women at high risk take up to 5mg folic acid per day for two months prior to conception.<sup>5 6</sup> However, it is essential to be mindful. High levels of unmetabolized folic acid can mask B12 deficiencies (so women taking high doses of folic acid should consecutively take at least 2.6mcg vitamin B12 per day), and have been linked with increasing cancer risk, which is why the Upper Level for folate is set at 1mg per day.<sup>7 8</sup>

### Folate terminology

*Folate* – is the naturally occurring form of vitamin B9 (ie. Found in food).<sup>9</sup> It is also used as a generic name for a group of related compounds with similar nutritional properties, also known as vitamin B9. The best choice for most people.

*Folic acid* – synthetic folate found in supplements and fortified foods. Only a small percentage of folic acid is converted to 5MTHF so can result in high levels of unmetabolized folic acid. However, it is cheap and helps to boost vitamin B9 levels for most people.

*Folinic acid (5-formyl tetrahydrofolate)* – the ‘active’ metabolite of folic acid. Supplementation with folinic acid alleviates the need for the enzyme dihydrofolate reductase (DHFR) and bypasses the deconjugation and reduction steps that are required with folic acid supplementation. Bioavailability of folinic acid appears to be high, with human absorption studies showing a bioavailability of 92%.<sup>10</sup>

*5 methyltetrahydrofolate (5MTHF)* – the ‘active’ form of folate. ‘Folate’ is converted to 5MTHF in the digestive system. Can also be purchased as a supplement, but is usually a lot more expensive than folic acid or folinic acid. Cheaper methylfolate supplements on the market may contain both the active 6S (otherwise known as the L- isomer) and the inactive 6R isomers of methylfolate which are less effective than using the pure active L- form.

*Levomefolic acid/levomefolate* – another term for 5MTHF

*Activated folate* – another term for 5MTHF

*Methylated folate/methylfolate* – another term for 5MTHF

## MTHFR

When folate-rich foods are consumed, enzymes convert folate to folinic acid so it can be used by the body.<sup>11</sup> Some women carry a genetic mutation from only one parent that could decrease the activity of this enzyme (MDHF reductase). However, as they have the other set of genes without the mutation, they will generally not have any symptoms. Approximately 2-16% women will be homozygous, meaning that this mutation is inherited from both gene lines and this can cause a deficiency of the enzyme needed for appropriate folate absorption.

The enzyme methylenetetrahydrofolate reductase (MTHFR) directs folate species either to DNA synthesis or to homocysteine (Hcy) remethylation. The common MTHFR C677T polymorphism affects the activity of the enzyme and hence folate distribution. Under conditions of impaired folate status, the homozygous TT genotype has been regarded as harmful because it is associated with a high concentration of plasma total Hcy, which is identified as a risk factor for occlusive disease in the coronary, cerebral and peripheral arteries and for venous thrombosis, and has also been related to the occurrence of neural tube and other birth defects and pregnancy complications. Any period of rapid growth increases the need for healthy DNA production. Increased demand for the production of healthy DNA is huge during pregnancy due to the intense growth of the foetus.

It is thought these diseases result from:

1. Impaired DNA synthesis and repair
2. Changes in methylation that negatively change gene expression
3. If there is a mutated MTHFR gene, the availability of active methyl folate is decreased, then DNA production and gene expression cannot happen as abundantly as required for the growing baby

4. This is when developmental disorders occur in offspring, such as neural tube defects, congenital heart disease, Down's Syndrome and cleft lip/palate

The MTHFR gene sits on Chromosome 1. There are two key variants commonly tested for MTHFR C677T and MTHFR A1298C.

#### **MTHFR mutations**

Heterozygous = 1 copy of the gene from either parent

Homozygous = 1 copy of the gene from each parent

MTHFR C677T Heterozygous = 40% loss of function

MTHFR C677T Homozygous = 70% loss of function

MTHFR A1298C Heterozygous = 20% loss of function

MTHFR A1298C Homozygous = 40% loss of function

MTHFR C677T & MTHFR A1298C heterozygous = compound heterozygous = 50% loss of function.

By taking standard folic acid supplements, the folic acid isn't converted to its active form and can result in high serum folate and low bioavailability of folate which may result in subfertility or Neural Tube Defects. Consequently, folinic acid or 5MTHF supplements are recommended in clients who have a poor intake of folate-rich foods and are homozygous for MTHFR C677T.

#### **Iodine**

Iodine deficiency has become a big issue over the past decade for women who are trying to conceive. Iodine is important for the development of the thyroid hormones. The thyroid gland regulates many metabolic processes, including growth and energy use. Iodine deficiency during early pregnancy can have serious consequences for the baby, such as stunted growth, diminished intelligence and retardation. In fact, it is the primary cause for preventable intellectual disability in children.

Iodine deficiency during pregnancy can result in abnormal function of the mother's thyroid and have a negative effect on the fetus' nervous system, increasing the risk of infant mortality.<sup>2</sup> Furthermore, a large observational study from the UK suggested that mild to moderate iodine deficiency in the first trimester of pregnancy may be associated with an adverse effect on child cognitive development.<sup>12</sup>

Iodine is sourced from a wide range of foods that come from the soil and sea. However, if soil is depleted of iodine, it impacts iodine levels of the food grown in it. Furthermore, iodine is particularly low in highly processed foods such as takeaway foods. To meet increased iodine needs during pregnancy, guidelines from Australia and the American Thyroid Association recommend that women planning to conceive take a supplement that contains 150mcg iodine per day.<sup>13</sup> Iodine supplements should not exceed a dose of 500mcg during pregnancy due to the increased risk of adverse effects to the foetus. Client's with Grave's disease should also be careful of taking excess iodine.<sup>14</sup>

#### **Iron**

Iron deficiency is believed to result in infertility.<sup>15</sup> Furthermore, during pregnancy a woman's plasma volume has been shown to increase by 50%, her red blood cell mass to increase by 18% and her haemoglobin mass to increase by 30% from average non-pregnant levels, resulting in a significant

need for increased iron.<sup>16</sup> Iron deficiency during pregnancy can result in adverse outcomes, both for mother and baby, such as low birth weight and infant developmental delay (both motor and mental function).<sup>17</sup> Additionally, more severe symptoms of attention-deficit hyperactivity disorder (ADHD) may be present in children with iron-deficiency anaemia.<sup>18</sup> Yet, the evidence supporting the benefit of iron supplementation during pregnancy is mixed. Some countries (such as Canada) recommend routine iron supplementation during pregnancy (16-20mg/day), yet others (such as the UK and Australia) recommend iron supplementation only in the presence of anemia.<sup>19</sup> This is because iron supplements can result in gastrointestinal upsets, can impact absorption of other minerals and high serum ferritin levels have been associated with an increased risk of Gestational Diabetes.<sup>20 21</sup> Consequently, it is recommended that a woman's iron status is optimised prior to conception. It is also important to note that large amounts of supplemental iron (greater than 25 mg) might also decrease zinc absorption (which is an essential nutrient for both fertility and pregnancy).<sup>22</sup> Taking iron supplements between meals helps decrease its effect on zinc absorption.

Serum ferritin is the best single diagnostic test for iron deficiency. A ferritin concentration below 15 µg /L for adults indicates iron deficiency. Supplementation should continue until iron stores are replenished and serum ferritin concentration is in the normal range; this usually takes 3-6 months. Supplemental iron is available in two forms: ferrous and ferric. Ferrous iron salts (ferrous fumarate, ferrous sulphate, and ferrous gluconate) are the best absorbed forms of iron supplements and usually contain 80-350mg ferrous iron salts (which converts to different amounts of iron depending upon the salt that it's combined with; however, iron is usually 30% of the salt). All oral iron supplements are non-haem and so adequate vitamin C levels are essential for adequate uptake.

### Vitamin B12

Vitamin B<sub>12</sub>, also known as cobalamin, is a water-soluble vitamin that plays a key role in the functioning of the brain and nervous system. It is also important in the metabolism and growth of cells. As mentioned above, high levels of unmetabolized folic acid can mask B12 deficiencies so women taking high doses of folic acid should consecutively take at least 2.6mcg vitamin B12 per day.<sup>5</sup>

Although B<sub>12</sub> deficiency is not overly common in most women, it can cause anaemia and be particularly dangerous for those trying to fall pregnant or in the early stages of pregnancy. Studies suggest that low vitamin B12 levels are associated with infertility and developmental abnormalities.<sup>23</sup> Inadequate vitamin B<sub>12</sub> can cause changes in blood that can increase the risk of abnormal egg development, ovulatory dysfunction as well as miscarriage.

Consequently, women at risk of B12 deficiency due to malabsorptive conditions (such as Crohn's disease or gastrointestinal surgery), diabetes, vegetarianism or poor diet have vitamin B12 levels tested and replaced as required.<sup>24 25</sup>

### Vitamin D

Vitamin D is a fat-soluble vitamin that is needed for the absorption of calcium. Daily requirements for vitamin D are around 800–1000 IU, but larger doses are needed for people who are already deficient.

The main source of Vitamin D is from exposure to UV sunlight and only a small amount (<10%) of daily Vitamin D requirements is obtained from dietary sources (~80-120IU/d). People who have

darker skin, have minimal sun exposure or who have excessive fat stores are at greater risk of deficiency.

Vitamin D receptors are distributed across various human tissues including ovaries, endometrium, placenta and the pituitary gland suggesting an active role of vitamin D in those tissues. As discussed earlier, there is accumulating evidence suggesting that vitamin D deficiency might be involved in the pathogenesis of insulin resistance and PCOS.<sup>26</sup> Moreover, vitamin D might influence steroidogenesis of sex hormones (estradiol and progesterone) in healthy women.<sup>27</sup> Vitamin D deficiency also has been reported to contribute to the pathogenesis of endometriosis due to its immunomodulatory and anti-inflammatory properties.<sup>28</sup> Although most studies support a role of vitamin D in the onset of these diseases (PCOS and endometriosis), randomized controlled trials to assess the efficacy of vitamin D supplementation have never been performed.

Studies investigating the association of vitamin D status with IVF outcomes reveal inconsistent results. In a study among 173 infertile women undergoing IVF, women with higher levels of 25(OH)D in serum and follicular fluid were significantly more likely to achieve clinical pregnancy following IVF.<sup>29</sup> Conversely, a study of Chinese women found that although lower serum vitamin D levels were associated with a lower fertilization rate, vitamin D level was not associated with an increased live birth rate following IVF.<sup>30</sup> However, most experts agree that vitamin D supplementation is a necessity, particularly in women suffering from obesity, insulin resistance or small ovarian reserve even though thus far research of vitamin D supplementation has not proven a significant difference in ovulation stimulation or embryo development.<sup>31</sup> It's interesting to note that UK guidelines recommend 10mcg (400IU) daily throughout pregnancy, and it's recommended that pregnant women should not consume greater than 4000IU on any one day.<sup>32</sup>

### Vitamin B6

Vitamin B6 is believed to play an important role in fertility. A systematic review of over 90,000 healthy women found that those who had higher B6 levels were more likely to conceive.<sup>33</sup>

Furthermore, emerging research suggests that vitamin B6 supplements may play an important role in increasing cervical mucus.<sup>34</sup> Increased levels of cervical mucus play an important role in fertility as it provides an increased window of time for the sperm to survive in a woman's vagina.

Deficiency of vitamin B6 is most commonly seen in women who consume alcohol regularly, women who have taken the oral contraceptive pill for a long time, and women with thyroid disease.

### Vitamin E

Vitamin E was discovered as an essential dietary factor for reproductive health in female rodents. Surprisingly, very little is known regarding human vitamin E status and reproductive health. In mice,  $\alpha$ -tocopherol sufficiency is essential for placentation.  $\alpha$ -TTP is expressed in the uterine wall of pregnant female mice and in the human placenta. Research in this field is of great importance because 96% of U.S. women do not meet vitamin E EAR.

Vitamin E ( $\alpha$ -tocopherol) is an exogenous, lipid-soluble antioxidant molecule. It is thought to be a direct free radical scavenger by activating the intracellular antioxidant enzymes and saving the cell membranes from lipid peroxidation, which was demonstrated on sperm membrane components. Its antioxidant effect was concluded in cancer therapy, high-risk pregnancy and male infertility.

Research undertaken in Turkey showed that Vit E supplementation (500 IU/day) in unexplained infertile patients may have beneficial effects in improving the endometrial thickness during controlled ovarian stimulation and IUI cycles.<sup>35</sup> Another important result of this study was the higher implantation and ongoing pregnancy rates observed in the Vit E-administered group, even though the differences were not significant. These improvements again may be a result of the improving antioxidant effect of Vit E on the endometrial receptivity.

Related with the effect of Vitamin E on the endometrium, the anticoagulant effect may be another reason for the improvement in the thickness. This anticoagulant activity may increase the blood supply to the follicles and the proliferating granulosa cells so that may increase the estrogen production which may be one of the pathways to have a good endometrium. On the other hand, this anticoagulant effect may directly increase the endometrial blood flow that may improve endometrial development.

In cases with likely oxidative stress, such as in women with unexplained infertility, Vitamin E may improve the endometrial environment via its antioxidant effect.<sup>36</sup> It may also modulate the antiestrogenic effect of ovulation induction, and the problem of a thin endometrium in these cycles may be adjusted.

### Selenium

Data pertaining to selenium status and female fertility and reproduction are sparse, with most studies focusing on the role of selenium in pregnancy. Only recently has some light been shed on its potential role in ovarian physiology.<sup>37</sup> The exact underlying molecular and biochemical mechanisms through which selenium modulate female reproduction are largely unknown, however selenium is a potent antioxidant, and recent studies suggest that the antioxidant effect may have an important role in both follicle growth and protection of embryonic tissues.<sup>38 39</sup>

### Choline

Choline is an essential nutrient that provides building materials for a range of different compounds that are used in a variety of different roles, however during pregnancy choline is an important nutrient for brain and spinal cord development. Adequate intake of this nutrient may help reduce the incidence of birth defects. Emerging research suggests that inadequate choline intake during pregnancy may also impact cognitive development in childhood (visual memory and processing speed) but further research is needed.<sup>40</sup>

Importantly, around 10-15% of the population have gene polymorphisms (SNPs) that reduce activity of key enzymes in the choline metabolism pathways. These individuals may have even higher dietary choline requirements.<sup>41</sup>

Research suggests that in pregnant women who have sufficient folic acid, increased intake of choline (amongst other nutrients) may offer additional risk reduction for neural tube defects.<sup>42</sup>

### Omega 3

Studies show that adequate amounts of Omega-3 are beneficial for a range of health conditions, including improving fertility (both natural conception and IVF) as it can reduce oxidative stress to reproductive organs and therefore minimise damage to eggs.<sup>43</sup>



A recent US study analysing over 500 couples who were trying to conceive found that among couples in which both the man and women consumed at least eight servings of seafood per cycle, fecundity (fertility) was 61% higher versus couples in which both partners consumed less than one serving of seafood per cycle.<sup>44</sup> Specifically, 92% of couples who consumed at least two servings of seafood per week were pregnant by 12 months in the study versus 79% among couples consuming less.

The World Association of Perinatal Medicine Dietary Guidelines recommends at least 200mg DHA and/or EPA Omega 3 fats each day before and during pregnancy, which equates to two oily fish meals per week. Fish is the best source of omega 3 polyunsaturated fats, with oily fish such as salmon, trout, sardines and mackerel providing over 2000mg Omega 3 per 150g serve. Other types of fish (which aren't so oily) such as John dory, snapper, blue-eye trevalla and bass still provide more than 200mg Omega 3 fats per serve. Seafood, eggs and lean red meat are also a source of omega 3, containing over 30mg of Omega 3 oils per serve.

## Zinc

Zinc is a basic building block for new cells, so ensuring the women get sufficient amounts is particularly important for the rapid cell growth that is needed for conception. Furthermore, zinc is also involved in immunity and insulin regulation, hence it plays an important role in fertility and pregnancy.

A study of 1060 Australian women found that those who had lower zinc levels took longer to conceive.<sup>45</sup> Another study of women undergoing IVF found that follicular fluid zinc levels were significantly higher ( $P < 0.001$ ) among participants who had undergone embryo transfer as compared to those who have not undergone embryo transfer, suggesting that higher zinc levels may optimise IVF outcomes.<sup>46</sup> One study also found a link between zinc levels and ovarian reserve.<sup>47</sup> Animal studies suggest that zinc deficiency disrupts oogenesis and meiotic division.<sup>48</sup>

As zinc is found primarily inside cells, blood tests for zinc are unreliable, which means there is no really good way to tell what a person's zinc stores are like. Plasma and urinary concentrations are probably the best indicators, however it is important to remember that results fluctuate widely. A comprehensive nutrition assessment considering a client's medical history and dietary intake is an important tool for determining zinc deficiency.<sup>49</sup> It is important to note that zinc absorption can be reduced in client's who undertake regular alcohol consumption, have malabsorptive conditions or have chronic liver disease.<sup>50</sup> Women following a vegetarian diet or who have a poor dietary intake may also be at risk of zinc deficiency.

In addition to considering the client's likelihood of zinc deficiency, it is also salient that interactions between zinc and copper be considered prior to administering zinc supplements as zinc and copper work against one another and compete for binding sites.<sup>51</sup> Supplements contain several forms of zinc, including zinc gluconate, zinc sulfate, and zinc acetate.<sup>22</sup> The percentage of elemental zinc varies by form. For example, approximately 23% of zinc sulfate consists of elemental zinc; thus, 220 mg of zinc sulfate contains 50 mg of elemental zinc. Research has not determined whether differences exist among forms of zinc in absorption, bioavailability, or tolerability. Most supplements provide 25-50mg elemental zinc which tends to be a typical dose used in practice; if prescribing a higher dose, consider if copper should be prescribed simultaneously to avoid deficiency.



## Chromium

Chromium is an essential mineral that has an essential role in carbohydrate and lipid metabolism. Women with PCOS commonly have decreased chromium levels, which has been linked to insulin resistance.<sup>52</sup> One randomised control trial indicated improvements in insulin sensitivity after supplementation with chromium picolinate (200mcg/day for three months) compared to metformin among women with PCOS who were resistant to clomiphen citrate.<sup>53</sup> No significant difference was found in ovulation or pregnancy rates. No other studies have reported beneficial effects of chromium supplementation on reproductive hormones or ovulation.

## Alternative Supplements

### CoenzymeQ10

Coenzyme Q10 (also known as CoQ10 or ubiquinone) is fat soluble and has many functions in the body including energy production and antioxidant activity.

The body is able to produce coenzyme Q10, however the amount we produce declines with age. There is little human research into CoQ10 for egg quality. CoQ10 is essential for mitochondrial activity so plays an important role in age-related oocyte quality and quantity decline.<sup>54</sup> Young, healthy ovaries produce relatively high levels of CoQ10 and are able to efficiently uptake CoQ10 from external sources. Diminished expression of the enzymes responsible for CoQ10 production, *Pdss2* and *Coq6*, was observed in oocytes of older females in both mouse and human. The age-related decline in oocyte quality and quantity may potentially be reversed or reduced by the administration of CoQ10.<sup>55</sup> Although it is most likely that the ovaries are the most beneficial target of Co Q10 supplementation, it is also possible that granulosa/cumulus cells and/or the uterine environment may also benefit and thus contribute to the increased reproductive capacity of CoQ10-treated females.<sup>56</sup> Additionally, CoQ10 works as a powerful antioxidant by preventing the action of free radicals.


Food sources are varied but include red meat, fish and avocado. CoQ10 supplementation generally has few significant side effects, although excessive doses can cause nausea and vomiting. However, it may decrease effectiveness of warfarin and other anticoagulants and have interactions with statins and beta-blockers. The medical community is yet to reach a consensus about the recommended dose for egg quality, however one study used a dose of 600mg twice per day oil-based ubiquinol (ubiquinol) for two months so currently this is the most common recommendation.<sup>57 58</sup> However, it is also essential to remember that dosing depends upon the type of CoQ10 used. Generally, CoQ10 dosing varies from 50mg to 600mg per day (spread across the day), however up to 1200mg is considered safe.

### Melatonin

In recent years, the negative impact of oxidative stress on fertility has become widely recognised. Several studies have demonstrated its negative effect on the number and quality of retrieved oocytes and embryos following IVF. Melatonin, a pineal hormone that regulates circadian rhythms, has also been shown to exhibit unique oxygen scavenging abilities.<sup>59</sup> Some studies have suggested a role for melatonin in gamete biology. Clinical studies also suggest that melatonin supplementation in IVF may lead to better pregnancy rates.



In humans, the only data on cyclical melatonin changes comes from women undergoing ovarian stimulation. Levels of melatonin dip in the pre-ovulatory phase and peak in the luteal phase. This suggests that melatonin has variable effects depending on the menstrual phase. It is also well known that shift-workers are more likely than daytime workers to experience circadian disruption and longer menstrual cycles, more menorrhagia and dysmenorrhoea.<sup>60</sup> These results are corroborated by a very large cohort study, which also found that duration of shiftwork was modestly associated with menstrual cycle irregularity.<sup>61</sup> A Japanese study found that melatonin levels varied significantly between night and day shift workers, while LH and FSH levels did not, suggesting that the menstrual irregularity associated with shiftwork could be explained by melatonin fluctuations.<sup>62</sup> These findings are in line with central effects on the hypothalamic pituitary axis, being capable of modifying the release of gonadotrophins and GnRH. In fact, in very high doses, when combined with progesterone, melatonin has the ability to suppress ovulation in humans, possibly by interfering with LH release.<sup>63</sup> This may represent inhibition of ovulation during darker months designed to prevent the birth of offspring when resources are less abundant.



**Figure 1:** Relationship between melatonin cycle and menstrual cycle.<sup>64</sup>

Other human studies have been promising, but unfortunately, have also been challenged by design limitations.<sup>65</sup> Generally positive results may be seen with 3mg nocte of oral melatonin from day 3–5 of their cycle up until administration of the human chorionic gonadotrophin (HCG) trigger. It is recommended that doses greater than 5mg not be taken as a starting dose as it can disrupt the circadian rhythm.

Research demonstrated that women taking melatonin before their IVF cycle had 50% of their eggs successfully fertilized, compared to 23% of the eggs which had not received melatonin.<sup>66</sup> Following embryo transfer, 19% of women taking melatonin supplements became pregnant compared to 10% of women who didn't. Supporting these findings, a systematic review found melatonin supplementation during IVF increased pregnancy rate by 21%.<sup>67</sup>

### Alpha-lipoic acid

Alpha-lipoic acid is an antioxidant that that body can produce naturally (in the mitochondria) but is also found in supplements and food (red meat, broccoli and tomatoes are excellent food sources). It's been gaining increased attention (particularly as a supplement) for its impacts on lowering blood glucose levels, reducing inflammation and weight loss (amongst other benefits) – which are beneficial for fertility.<sup>68 69 70</sup> It has particularly been gaining popularity for women with PCOS. For example, a case control study of forty-one women with PCOS found that on a combination of alpha-lipoic acid and d-chiro inositol, 76.7% women reported improved menstrual cyclicity and 40% women had ovulation restored.<sup>71</sup> A fascinating study of alpha-lipoic acid on non-obese women with

PCOS who had all previously undergone ICSI found a significant increase in grade 1 embryos after taking alpha-lipoic acid, however, there was no difference in fertilization rates.<sup>72</sup>

Though there is no set dosage, most evidence suggests that 300–800 mg is sufficient and safe, with anecdotally the most commonly prescribed dose being 600mg per day.<sup>73</sup> Research shows that adults can take up to 2,400 mg without harmful side effects.<sup>74</sup> Higher doses are not recommended, as there is no evidence that they provide extra benefits.<sup>75</sup> As few safety studies have been undertaken during pregnancy, it is recommended that it be ceased after a transfer. Supplementation with alpha-lipoic acid usually yields best results for women with PCOS when taken with myo-inositol as the two have a synergistic effect.<sup>73</sup> To date, even fewer studies have been undertaken on reproductive benefits for women without PCOS. Alpha-lipoic acid supplements are best taken on an empty stomach, as certain foods can lower the acid's bioavailability.

### Inositols

Myo-inositol and D-chiro-inositol are involved in the insulin signalling pathways. More specifically, myo-inositol is involved in cellular glucose uptake and FSH signalling, and D-chiro-inositol is involved in glycogen synthesis and androgen production. Inositols occur naturally in fruit, grains and nuts. Current research indicates that these supplements may improve insulin sensitivity, menstrual regularity and ovulation rate among women with PCOS.<sup>76</sup>

It is important to note that the safety of inositols has not been adequately studied. For example, emerging evidence suggests that D-chiro-inositol treatment may be beneficial when administered in low doses, yet the progressive increase of its dosage has been associated with worsening oocyte quality.<sup>77 78</sup> Furthermore, intestinal absorption of myo-inositol is reduced by the simultaneous administration of D-chiro-inositol since the two stereoisomers compete with each other for the same transporter that has similar affinity for each of them.<sup>79</sup> Clinical evidence has demonstrated that the 40 : 1 ratio (2g twice per day) between myo-inositol and D-chiro-inositol is the optimal combination to restore ovulation in PCOS women.<sup>80</sup> Common ratios in supplements tend to be 2000mg myo-inositol to 50mg D-chiro-inositol or 1100mg myo-inositol and 28mg D-chiro-inositol. Myo-inositol seems to be safe in doses up to 4,000mg per day even during pregnancy and up to 12,000mg per day before side effects commence.<sup>81</sup> Supplements are usually taken 15 minutes prior to meals.

### L-Arginine

L-Arginine is (a non-essential amino acid) involved in protein synthesis. It also has antioxidant properties that aid in the inflammatory response and act against oxidative damage. A small study found that supplementation helped improve rates of pregnancy by 18%.<sup>82</sup> It is believed that it may help improve circulation to reproductive organs, that may enhance oocyte development and implantation. However, it is primarily used for increasing endometrial blood flow.<sup>83</sup> However, to date, there is no clear evidence of an increase in clinical pregnancy rates, although further research needs to be conducted.<sup>84</sup> However, one study suggested that L-arginine supplementation may be detrimental to embryo quality, so if used it should be commenced after egg collection, prior to transfer.<sup>85 86</sup>

### Maca

Maca is most commonly consumed as a powdered supplement added to smoothies and juices, however, can also be found in supplements. It was traditionally known as an aphrodisiac. Although it is a popular fertility supplement, there is very little evidence-based research, especially in females.<sup>87</sup>

### Royal jelly

Royal jelly is made by nurse worker bees to feed to larvae in the first few days of their life. If larvae are fed royal jelly exclusively for a longer period, the larvae will actually develop into a queen bee, hence where the name 'royal' comes from. A queen bee lives exclusively on royal jelly and this allows her to lay up to 2,000 eggs per day. There are claims that the royal jelly can help balance out hormones in the bee to improve egg laying ability.

Royal jelly has been traditionally used to treat menopause symptoms by rebalancing the hormonal concentration in the blood, decreasing FSH and increasing the estrogen concentration.<sup>88</sup> Animal studies suggest that royal jelly may improve oocyte quality, so human studies are desperately needed.<sup>89</sup> Furthermore, royal jelly is rich in antioxidants (flavonoids, phenolic acids and terpenoids), may improve insulin sensitivity and has an anti-inflammatory effect.<sup>90 91 92</sup>

There are no recommended dosing guidelines as limited human studies have been undertaken, however studies tend to use between 50mg to 6000mg per day. Safety studies have not been undertaken during pregnancy, so it is recommended that it be ceased prior to an embryo transfer. Women who have an allergy to bees should also avoid these supplements.

### Soy

Soy is rich in phytoestrogens, so it is not surprising that soy supplements are a popular adjunct. Evidence from human studies, while limited, has so far not shown little evidence of harm for females.<sup>93</sup>

One small study found that soy supplements improved ovulation.<sup>94</sup> In a prospective cohort of women undergoing IVF in the US, the odds of achieving a live birth during ART were 77% higher for women with the highest intake of soy isoflavones (mean: 12mg/d; range: 8–28mg/d) than for women who did not consume any soy products.<sup>95</sup> Similarly, isoflavone supplements (120mg/d of isoflavones) increased live birth rates (36.7% versus 13.6%) in an RCT among couples undergoing infertility treatment with clomiphene citrate + timed intercourse.<sup>96</sup> Higher doses (1,500mg/d) have also been shown to increase endometrial thickness and ongoing pregnancy rates in women undergoing IUI (20.0% vs. 4.4%) and clinical pregnancy rates in women undergoing IVF (39.3% vs. 20.9%).<sup>97</sup>

A systematic review found that the amount of soy protein resulting in GI side-effects commenced at 20grams soy per day, and 40mg of pure isoflavones per day, although there was no clear dose relationship between the amount consumed and associated adverse events.<sup>98</sup> Effects of isoflavones depend on varied factors including the dose, duration of use, protein binding affinity, the individual's metabolism and intrinsic estrogenic state, as well as the source of the isoflavones.<sup>99</sup>

## References

- <sup>1</sup> Chavarro, J.E., et al., *Use of multivitamins, intake of B vitamins and risk of ovulatory infertility*. Fertil Steril, 2008. **89**(3): p. 688-676.
- <sup>2</sup> Department of Health and Ageing, *Clinical Practice Guidelines: Antenatal Care – Module 1*. National Health and Medical Research Council, 2012. Available at: <https://oysconmelibrary01.files.wordpress.com/2016/09/clinical-practice-guidelines-antenatal-care-module-11.pdf>
- <sup>3</sup> Kennedy, D., et al., *Identifying women who might benefit from higher doses of folic acid in pregnancy*. Can Fam Physician, 2012. **58**(4); p. 394-397.
- <sup>4</sup> Parker, S.E., et al., *The impact of folic acid intake on the association between diabetes, obesity, and spina bifida*. Am J Obstet Gynecol, 2013. **209**(3): e1-239.
- <sup>5</sup> Wilson, R.D., et al., *Pre-conception folic acid and multivitamin supplementation for the primary and secondary prevention of neural tube defects and other folic acid-sensitive congenital anomalies*. J Obstet Gynaecol Can, 2015. **37**(6): p. 534-552.
- <sup>6</sup> Centers for Disease Control, *Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural defects*. MMWR, 1992. Available at: <https://www.cdc.gov/mmwr/preview/mmwrhtml/00019479.htm>
- <sup>7</sup> Rees, J.R., et al., *Unmetabolized folic acid, tetrahydrofolate, and colorectal adenoma risk*. Cancer Prev Res (Phila), 2017. **10**(8): p. 451-458.
- <sup>8</sup> Centers for Disease Control and Prevention, *Folic Acid Safety, Interactions, and Effects on Other Outcomes*. Centers for Disease Control and Prevention, 2017. Available at: [https://www.cdc.gov/ncbddd/folicacid/faqs/faqs-safety.html#:~:text=The%20tolerable%20upper%20intake%20level%20\(UL\)%20for%20folic%20acid%20was,of%205%2C000%20mcg%2Fday%2015.](https://www.cdc.gov/ncbddd/folicacid/faqs/faqs-safety.html#:~:text=The%20tolerable%20upper%20intake%20level%20(UL)%20for%20folic%20acid%20was,of%205%2C000%20mcg%2Fday%2015.)
- <sup>9</sup> Scaglione, F., and Panzavolta, G., *Folate, folic acid and 5-methyltetrahydrofolate are not the same thing*. Xenobiotica, 2014. **44**(5): p. 480-488.
- <sup>10</sup> McGuire, B.W., et al., *Pharmacokinetics of leucovorin calcium after intravenous, intramuscular, and oral administration*. Clin Pharm, 1988. **7**(1): p. 52-58.
- <sup>11</sup> Goldblatt, J., *MTHFR genetic testing: Controversy and clinical implications*. Men's Health, 2016. **45**(4): p. 237-240.
- <sup>12</sup> Bath, S.C., et al., *Effect of inadequate iodine status in UK pregnant women on cognitive outcomes in their children: Results from the Avon longitudinal study of parents and children (ALSPAC)*. Lancet, 2013. **382**(9889): p. 331-337.
- <sup>13</sup> Leung, A.M., et al., *Potential risks of excess iodine ingestion and exposure: Statement by the American Thyroid Association Public Health Committee*. Thyroid, 2015. **25**(2): p. 145-146.
- <sup>14</sup> Markou, K., et al., *Iodine-induced hypothyroidism*. Thyroid, 2001. **11**(5): p. 501-510.
- <sup>15</sup> Petkus, D.L., et al., *The unexplored crossroads of the female athlete triad and iron deficiency: A narrative review*. Sports Med, 2017. **47**(9): p. 1721-1737.
- <sup>16</sup> Hytten, F., *Blood volume changes in normal pregnancy*. Clin Haematol, 1985. **14**(3): p. 601-612.
- <sup>17</sup> Berglund, S.K., *The impacts of maternal iron deficiency and being overweight during pregnancy on neurodevelopment of the offspring*. Brit J Nutr, 2017. **118**(7): p. 533-540.
- <sup>18</sup> Wang, Y., Huang, L., and Mu, D., *Iron status in attention-deficit/hyperactivity disorder: A systematic review and meta-analysis*. PLoS One, 2017. **12**(1): e0169145.
- <sup>19</sup> Government of Canada, *Prenatal Nutrition*. Government of Canada, 2019. Available at: <https://www.canada.ca/en/health-canada/services/canada-food-guide/resources/prenatal-nutrition.html>
- <sup>20</sup> Donangelo, C.M., *Supplemental zinc lowers measures of iron status in young women with low iron reserves*. J Nutr, 2002. **132**(7): p. 1860-1864.

- <sup>21</sup> Khambalia, A.Z., et al., *High maternal iron status, dietary iron intake and iron supplement use in pregnancy and risk of gestational diabetes mellitus: A prospective study and systematic review*. Diabet Med, 2016. **33**(9): p. 1211-1221.
- <sup>22</sup> National Institute of Health, Zinc. National Institute of Health – Office of Dietary Supplements, 2020. Available at: <https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/>
- <sup>23</sup> Bernard, D.J., et al., *Mice lacking the transcobalamin – vitamin B12 receptor, CD320, suffer from anemia and reproductive deficits when fed vitamin B12 – deficient diet*. Hum Mol Genet, 2018. **27**(20): p. 3627-3640.
- <sup>24</sup> Stabler, S.P., and Allen, R.H., *Vitamin B12 deficiency as a worldwide problem*. Annu Rev Nutr, 2004. **24**: p. 299-326.
- <sup>25</sup> Jacobson-Bensky, M., et al., *Comparison of sublingual vs. intramuscular administration of vitamin B12 for the treatment of patients with vitamin B12 deficiency*. Drug Deliv Transl Res, 2019. **9**(3): p. 625-630.
- <sup>26</sup> Anagnostis, P., Karras, S., and Goulis, D.G., *Vitamin D in human reproduction: A narrative review*. Int J Clin Pract, 2013. **67**(3): p. 225-235.
- <sup>27</sup> Lerchbaum, E., and Obermayer-Pietsch, B., *Vitamin D and fertility: A systematic review*. Eur J Endocrinol, 2012. **166**(5): p. 765-778.
- <sup>28</sup> Muscogiuri, G., et al., *Shredding new light on female fertility: The role of vitamin D*. Rev Endocr Metab Disord, 2017. **18**(3): p. 273-283.
- <sup>29</sup> Garbedian, K., Boggild, M., and Liu, K.E., *Effect of vitamin D status on clinical pregnancy rates following in vitro fertilization*. CMAJ Open, 2013. **1**(2): e77-E82.
- <sup>30</sup> Liu, X., et al., *Effect of vitamin D status on normal fertilization rate following in vitro fertilization*. Reprod Biol Endocrinol, 2019. **17**(1): p. 59.
- <sup>31</sup> Dabrowski, F.A., Grzechocinska, B., and Wielgos, M., *The role of vitamin D in reproductive health – A trojan horse of the golden fleece?* Nutrients, 2015. **7**(6): p. 4139-4153.
- <sup>32</sup> National Institute for Health and Care Excellence (NICE), *Antenatal care for uncomplicated pregnancies – Clinical guideline [CG62]*. NICE: United Kingdom, 2019. Available at: <https://www.nice.org.uk/guidance/cg62>
- <sup>33</sup> Buhling, K.J., and Grajecki, D., *The effect of micronutrient supplements on female fertility*. Curr Opin Obstet Gynecol, 2013. **25**(3): p. 173-180.
- <sup>34</sup> Keefe, C.E., Mirkes, R., and Yeung, P., *The evaluation and treatment of cervical factor infertility a medical-moral analysis*. Linacre Q, 2012. **79**(4): p. 409-425.
- <sup>35</sup> Cicek, N., et al., *Vitamin E effect on controlled ovarian stimulation of unexplained infertile women*. J Assist Reprod Genet, 2012. **29**(4): p. 325-328.
- <sup>36</sup> Traber, M.G., and Manor, D., *Vitamin E*. Adv Nutr, 2012. **3**(3): p. 330-331.
- <sup>37</sup> Qazi, I.H., et al., *Selenium, selenoproteins, and female reproduction: A review*. Molecules, 2018. **23**(12): p. 3053.
- <sup>38</sup> Paszkowski, T., et al., *Selenium dependent glutathione peroxidase activity in human follicular fluid*. Clin Chim Acta, 1995. **236**(2): p. 173-180.
- <sup>39</sup> Baek, I.J., et al., *Differential expression of gastrointestinal glutathione peroxidase (GI-GPx) gene during mouse organogenesis*. Anat Histol Embryol, 2011. **40**(3): p. 2010-218.
- <sup>40</sup> Mun, J.G., et al., *Choline and DHA in maternal and infant nutrition: Synergistic implications in brain and eye health*. Nutrients, 2019. **11**(5): p. 1125.
- <sup>41</sup> Halova, A., Janoutova, J., and Sery, O., *CHAT gene polymorphism rs3810950 is associated with the risk of Alzheimer's disease in the Czech population*. J Biomed Sci, 2018. **25**: p. 41.
- <sup>42</sup> Petersen, J.M., *One-carbon cofactor intake and risk of neural tube defects among women who meet folic acid recommendations: A multicentre case-control study*. Am J Epidemiol, 2019. **188**(6): p. 1136-1143.
- <sup>43</sup> Lass, A., and Belluzzi, A., *Omega-3 polyunsaturated fatty acids and IVF treatment*. Reprod Biomed Online, 2019. **38**(1): p. 95-99.
- <sup>44</sup> Gaskins, A.J., *Seafood intake, sexual activity, and time to pregnancy*. J Clin Endocrin Metab, 2018. **103**(7): p. 2680-2688.
- <sup>45</sup> Grieger, J.A., et al., *Maternal selenium, copper and zinc concentrations in early pregnancy, and the association with fertility*. Nutrients, 2019. **11**(7): p. 1609.
- <sup>46</sup> Kumar, S., et al., *Role of environmental factors and oxidative stress with respect to invitro fertilization outcome*. Indian J Med Res, 2018. **148**(Suppl): S125-S133.



- <sup>47</sup> Moslehi, N., et al., *Current evidence on associations of nutritional factors with ovarian reserve and timing of menopause: A systematic review*. Adv Nutr, 2017. **8**(4): p. 597-612.
- <sup>48</sup> Hester, J., Hanna-Rose, W., and Diaz, F., *Zinc deficiency reduces fertility in C. Elegans Hermaphrodites and disrupts oogenesis and meiotic progression*. Comp Biochem Physiol C Toxicol Pharmacol, 2017. **191**:203-209.
- <sup>49</sup> Wieringa, F.T., Dijkhuizen, M.A., and Berger, J., *Determination of zinc status in humans: Which indicator should we use?* Nutrients, 2015. **7**(5): p. 3252-3263.
- <sup>50</sup> Prasad, A.S., *Discovery of human zinc deficiency: Its impact on human health and disease*. Adv Nutr, 2013. **4**(2): p. 176-190.
- <sup>51</sup> Pre-conception Health Special Interest Group, *Micronutrient (zinc and selenium) supplements and subfertility - Evidence review*. The Fertility Society of Australia, N.D. Available at: <https://www.fertilitysociety.com.au/wp-content/uploads/FSA-Micronutrient-Zinc-and-Selenium-supplements-and-subfertility.pdf>
- <sup>52</sup> Chakraborty, P., et al., *Altered trace mineral milieu might play an aetiological role in the pathogenesis of polycystic ovary syndrome*. Biol Trace Elem Res, 2013. **152**(1): p. 9-15.
- <sup>53</sup> Amooee, S., et al., *Metformin versus chromium picolinate in clomiphene citrate-resistant patients with PCOs: A double-blind randomized clinical trial*. Iran J Reprod Med, 2013. **11**(8): p. 611-618.
- <sup>54</sup> Ben-Meir, A., et al., *Coenzyme Q10 restores oocyte mitochondrial function and fertility during reproductive aging*. Aging Cell, 2015. **14**(5): p. 887-895.
- <sup>55</sup> Giannubilo, S.R., *CoQ10 supplementation in patients undergoing IVF – ET: The relationship with follicular fluid content and oocyte maturity*. Antioxidants (Basel), 2018. **7**(10): p. 141.
- <sup>56</sup> Gat, I., et al., *The use of coenzyme Q10 and DHEA during IUI and IVF cycles in patients with decreased ovarian reserve*. Gynecol Endocrinol, 2016. **32**(7): p. 534-537.
- <sup>57</sup> Xu, Y., Nisenblat, V., and Wang, S., *Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: A randomized controlled trial*. Reprod Biol Endocrinol, 2018. **16**: p. 29.
- <sup>58</sup> Bentov, Y., Hannam, T., and Casper, R.F., *Coenzyme Q10 supplementation and oocyte aneuploidy in women undergoing IVF-ICSI treatment*. Clin Med Insights Reprod Health, 2014. **8**: p. 31-36.
- <sup>59</sup> Tamura, H., et al., *Melatonin and female reproduction*. J Obstet Gynaecol Res, 2014. **40**(1): p. 1-11.
- <sup>60</sup> Fernado, S., and Rombauts, L., *Melatonin: Shedding light on infertility? – A review of the recent literature*. J Ovarian Res, 2014. **7**: p. 98.
- <sup>61</sup> Lawson, C.C., Whelan, E.A., and Rich-Edwards, J.W., *Rotating shift work and menstrual cycle characteristics*. Epidemiol, 2011. **22**(3): p. 305-312.
- <sup>62</sup> Miyauchi, F., Nanjo, K., and Otsuka, K., *Effects of night shift on plasma concentrations of melatonin, LH, FSH and prolactin, and menstrual irregularity*. Sangyo Igaku, 1992. **34**(6): p. 545-550.
- <sup>63</sup> Tamura, H., et al., *Melatonin and the ovary: Physiological and pathophysiological implications*. Fertil Steril, 2009. **92**(1): p. 328-343.
- <sup>64</sup> Lakshmi, S., and Desai, A.A., *Quantum chemical computational methods for interpreting and predicting the vibrational spectra of menstrual cycle in women*. Elixir Appl Math, 2017. **103**: p. 45596-45601.
- <sup>65</sup> Reiter, R.J., et al., *Melatonin and the circadian system: Contributions to successful female reproduction*. Fertil Steril, 2014. **102**(2): p. 321-328.
- <sup>66</sup> Epigee Women's Health, *Melatonin and fertility*. Epigee Women's Health, 2010. Available at: <http://www.epigee.org/melatonin-and-fertility.html>
- <sup>67</sup> Seko, L., et al., *Melatonin supplementation during controlled ovarian stimulation for women undergoing assisted reproductive technology: Systematic review and meta-analysis of randomized controlled trials*. Fertil Steril, 2014. **101**(1): p. 154-161.
- <sup>68</sup> Akbari, M., et al., *The effects of alpha-lipoic acid supplementation on glucose control and lipid profiles among patients with metabolic diseases: A systematic review and meta-analysis of randomized controlled trials*. Metabolism, 2018. **87**: p. 56-69.
- <sup>69</sup> Saboori, S., et al., *Effects of alpha-lipoic acid supplementation on C-reactive protein level: A systematic review and meta-analysis of randomized controlled clinical trials*. Nutr Metab Cardio Disease, 2018. **28**(8): p. 779-786.
- <sup>70</sup> Kucukgoncu, S., et al., *Alpha-lipoic acid (ALA) as a supplementation for weight loss: Results from a meta-analysis of randomized controlled trials*. Obes Rev, 2017. **18**(5): p. 594-601.

- <sup>71</sup> Fruzzetti, F., et al., *Treatment with D-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome*. Gynecol Endocrinol, 2019. **35**(6): p. 506-510.
- <sup>72</sup> Rago, R., et al., *Effect of myo-inositol and alpha-lipoic acid on oocyte quality in polycystic ovary syndrome non-obese women undergoing in vitro fertilization: A pilot study*. J Biol Regul Homeost Agents, 2015. **29**(4): p. 913-23.
- <sup>73</sup> Fruzzetti, F., et al., *Clinical and metabolic effects of alpha-lipoic acid associated with two different doses of myo-inositol in women with polycystic ovary syndrome*. Int J Endocrinol, 2020. **2020**: e2901393.
- <sup>74</sup> Cremer, D.R., et al., *Safety evaluation of a-lipoic acid (ALA)*. Regul Toxicol Pharmacol, 2006. **46**(1): p. 29-41.
- <sup>75</sup> Jacob, S., et al., *Oral administration of RAC – alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: A placebo-controlled pilot trial*. Free Radic Biol Med, 1999. **27**(3-4): p. 309-14.
- <sup>76</sup> Unfer, V., et al., *Effects of myo-inositol in women with PCOS: A systematic review of randomized controlled trials*. Gynecol Endocrinol, 2012. **28**(7): p. 509-515.
- <sup>77</sup> Lagana, A.S., Barbaro, L., and Pizzo, A., *Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-chiro-inositol*. Arch Gynecol Obstet, 2015. **291**(5): p. 1181-1186.
- <sup>78</sup> Isabella, R., and Raffone, E., *CONCERN: Does ovary need D-chiro-inositol?* J Ovarian Res, 2012. **5**: p. 14.
- <sup>79</sup> Roseff, S., and Montenegro, M., *Inositol treatment for PCOS should be science-based and not arbitrary*. Int J Endocrinol, 2020. **2020**: e6461254.
- <sup>80</sup> Nordio, M., Basciani, S., and Camajani, E., *The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: Comparison with other ratios*. **23**(12): p. 5512-5521.
- <sup>81</sup> Carlomagno, G., and Unfer, V., *Inositol safety: Clinical evidences*. Eur Med Pharmacol Sci, 2011. **15**(8): p. 931-936.
- <sup>82</sup> Westphal, L.M., et al., *A nutritional supplement for improving fertility in women – A pilot study*. J Reprod Med, **49**(4).
- <sup>83</sup> Takasaki, A., Tamura, H., and Sugino, N., *Luteal blood flow and luteal function*. J Ovarian Res, 2009. **2**: p. 1.
- <sup>84</sup> Showell, M.G., Mackenzie-Proctor, R., and Hart, R.J., *Antioxidants for female subfertility*. Cochrane Database Syst Rev, 2017. **2017**(7): CD007807.
- <sup>85</sup> Battaglia, C., et al., *Adjuvant L-arginine treatment in controlled ovarian hyperstimulation: A double-blind randomized study*. Hum Reprod, 2002. **17**(3): p. 659-65.
- <sup>86</sup> Lebovitz, O., and Orvieto, R., *Treating patients with “thin” endometrium – An ongoing challenge*. Gynecol Endocrinol, 2014. **30**(6): p. 409-414.
- <sup>87</sup> Beharry, S., and Heinrich, M., *Is the hype around the reproductive health claims of maca (Lepidium meyenii walp.) justified?* J Ethnopharmacol, 2018. **211**: p. 126-170.
- <sup>88</sup> Seyyedi, F., Rafiean-Kopaei, M., and Miraj, S., *Comparison of the effects of the vaginal royal jelly and vaginal estrogen on quality of life, sexual and urinary function in postmenopausal women*. J Clin Diagn Res, 2016. **10**(5): QC01-05.
- <sup>89</sup> Pasupuleti, V.R., et al., *Honey, propolis, and royal jelly: A comprehensive review of their biological actions and health benefits*. Oxid Med Cell Longev, 2017. **2017**: e1259510.
- <sup>90</sup> Kocot, J., et al., *Antioxidant potential of propolis, bee pollen, and royal jelly: Possible medical application*. Oxid Med Cell Longev, 2018. **2018**: e7074209.
- <sup>91</sup> Morita, H., et al., *Effect of royal jelly ingestion for six months on healthy volunteers*. Nutr J, 2012. **11**: p. 77.
- <sup>92</sup> Khazaei, M., Ansarian, A., and Ghanbari, E., *New findings on biological actions and clinical applications of royal jelly: A review*. J Diet Suppl, 2018. **15**(5): p. 757-775.
- <sup>93</sup> Gaskins, A.J., and Chavarro, J.E., *Diet and fertility: A review*. Am J Obstet Gynecol, 2018. **218**(4): p. 379-389.
- <sup>94</sup> Kohama, T., Kobayashi, H., and Inoue, M., *The effect of soybeans on the anovulatory cycle*. J Med Food, 2005. **8**(4): p. 550-551.
- <sup>95</sup> Vanegas, J.C., et al., *Soy food intake and treatment outcomes of women undergoing assisted reproductive technology*. Fertil Steril, 2015. **103**(3): p. 749-755.
- <sup>96</sup> Shahin, A.Y., et al., *Adding phytoestrogens to clomiphene induction in unexplained infertility patients – A randomized trial*. **16**(4): p. 580-588.



---

<sup>97</sup> Unfer, V., et al., *High dose of phytoestrogens can reverse the antiestrogenic effects of clomiphene citrate on the endometrium in patients undergoing intrauterine insemination: A randomized trial.* J Soc Gynecol Investig, 2004. **11**(5): p. 323-328.

<sup>98</sup> Hooper, L., et al., *Effect of soy protein and isoflavones on circulating hormone concentrations in pre- and post-menopausal women: A systematic review and meta-analysis.* Hum Reprod Update, 2009. **15**(4): p. 423-440.

<sup>99</sup> Cassidy, A., *Potential risks and benefits of phytoestrogen-rich diets.* Int J Vitam Nutr Res, 2003. **73**(2): p.120-126.